Clinical Trials

Cardiol Therapeutics is currently conducting a Phase II open-label pilot study (NCT05494788) to evaluate CardiolRx™ in patients with recurrent pericarditis. The study will measure changes in patient-reported pain and other clinical markers over an 8-week period, with a total of 25 patients to be enrolled.

Answer last refreshed: 2026-08-18